¸ßЧҺÏàÉ«Æסª´®ÁªÖÊÆ×·¨²â¶¨°¢Íз¥ËûÍ¡µÄѪҩŨ¶È_ҩѧרҵ±ÏÒµÂÛÎÄ
·¢²¼Ê±¼ä£º
2014-11-09
À´Ô´£º
ÈË´ó¾¼ÃÂÛ̳
¡¾ÕªÒª¡¿Ä¿µÄ ½¨Á¢¸ßЧҺÏàÉ«Æ×´®ÁªÖÊÆ×·¨²â¶¨°¢Íз¥Ëû͡ѪҩŨ¶ÈµÄ·½·¨¡£·½·¨ ²ÉÓô¿ÒÒë泬ÉùÌáÈ¡£¬¸ßËÙÀëÐijÁµíµ°°×ºó£¬ÒÔÒÒëæ-ÒÒËá炙º³åÒº×÷ΪÁ÷¶¯Ï࣬Phenomenex Luna 3¦Ì C18(2) 100 A (150¡Á2.00mm 3¦Ìm)·´ÏàÉ«Æ×Öù£¬ÔÚÕýÀë×ÓģʽÏÂÒÔµçÅçÎíµçÀë´®ÁªÖÊÆ×½øÐвⶨ¡£½á¹û Ѫ½¬Öа¢Íз¥ËûÍ¡µÄÏßÐÔ·¶Î§Îª0.1-20 ng/mL£¬¶¨Á¿ÏÞΪ 0.1 ng/mL¡£·½·¨»ØÊÕÂÊΪ 96%¡«103%£¬ÈÕ¼ä ¡¢ÈÕÄÚRSD ¾ùСÓÚ6%¡£ ½áÂÛ ±¾·½·¨¼òµ¥¡¢ÁéÃô¡¢×¼È·£¬ÊÊÓÃÓÚ°¢Íз¥ËûÍ¡ÈËÌåѪҩŨ¶ÈµÄ¼ì²â¡£
¡¾¹Ø¼ü´Ê¡¿°¢Íз¥ËûÍ¡ ѪҩŨ¶È ¸ßЧҺÏàÉ«Æ×´®ÁªÖÊÆ×·¨(LC-MS/MS)
°¢Íз¥ËûÍ¡¸ÆƬÊÇËûÍ¡ÀàѪ֬µ÷½ÚÒ©£¬Îª3-ôÇ»ù-3-¼×»ùÒ»Îì¶þõ£¸¨Ã¸A(HMG-CoA)»¹ÔøÒÖÖƼÁ[1]£¬ËüÄܹ»½µµÍѪ½¬µ¨¹Ì´¼ºÍÖ¬µ°°×ˮƽ£¬¼õÉÙµÍÃܶÈÖ¬µ°°×µÄÉú³É£¬ÁÙ´²ÉÏÓÃÓÚ¼Ò×åÐԸߵ¨¹Ì´¼ÑªÖ¢¡¢»ìºÏÐÔ¸ß֬Ѫ֢µÈÖ¢¡£ÒòÆä½µÖ¬×÷ÓÃÇ¿£¬¸±×÷ÓÃС£¬ÔÚ¸ß֬Ѫ֢£¬ÌرðÊǸߵ¨¹Ì´¼ÑªÖ¢µÄÖÎÁÆÖеõ½¹ã·ºÓ¦Óà [2]¡£±¾ÎĽ¨Á¢Á˸ßЧҺÏàÉ«Æ×´®ÁªÖÊÆ×·¨²â¶¨Ñª½¬ÑùÆ·Öеİ¢Íз¥ËûÍ¡£¬±¾·¨×¨ÁéÃô¶È¸ß¡¢ÖØÏÖÐԺã¬ÑùÆ·´¦Àí·½·¨¼ò±ã¡£»¯Ñ§½á¹¹¼ûͼ1¡£
ͼ1 °¢Íз¥ËûÍ¡µÄ½á¹¹Ê½
Fig.1 Structure of Atorvastatin
1 ʵÑ鲿·Ö
1.1²ÄÁϺÍÊÔ¼Á
°¢Íз¥ËûÍ¡±ê׼Ʒ¹º×ÔÖйúÒ©Æ·ÉúÎïÖÆÆ·¼ì¶¨Ëù;Ç°´¦ÀíËùÓÃÒÒëæΪ·ÖÎö´¿£¬Á÷¶¯ÏàµÄÒÒëæΪɫÆ×´¿(µÂ¹ú MERCK);ʵÑéÓÃˮΪ³¬´¿Ë®£¬ÓÉ Milli-QϵͳÖÆ×÷(ÃÀ¹úMillipore¹«Ë¾)¡£
1.2ÒºÏàÉ«Æ×Ìõ¼þ
ÒºÏàÉ«Æ×ÒÇÆ÷Ϊµº½òProminence UFLC;É«Æ×ÖùÑ¡Óà Phenomenex Luna 3¦Ì C18(2) 100 A (150¡Á2.00mm 3¦Ìm);ÖùÎÂ40¡æ;Á÷¶¯ÏࣺÒÒëæÒÒËá炙º³åÒº(ÒÒËáï§5mmol/L¡¢¼×Ëá0.5%(v/v))(Ìå»ý±È6£º4)£¬µÈ¶ÈÏ´ÍÑ;½øÑùÁ¿10¦ÌL;Á÷ËÙ±£³ÖÔÚ0.3mL/min¡£
1.3ÖÊÆ×Ìõ¼þ
ÖÊÆ×ÒÇÆ÷ΪÃÀ¹úAB¹«Ë¾µÄAPI4000 Q-trap;µçÀ뷽ʽ£ºESI(+);Ñ¡Ôñ¶àÖØ·´Ó¦¼à(MRM);µçÀëµçѹ5500V£¬¸¨Öú¼ÓÈÈζÈ500¡æ£¬ÆøÁ±Æø30psi£¬Îí»¯Æø3psi£¬ÅöײÆø£ºÖеȣ¬Àë×ÓÔ´ÆøÌå1£º50psi£¬Àë×ÓÔ´ÆøÌå2£º60psi¡£°¢ÍÐËûÍ¡ÔÚESI(+)[M+H]+ µÄMRM ģʽϵÄÖÊÆײÎÊý¼û±í1¡£
1.4Ѫ½¬ÑùÆ·´¦Àí
¾«È·Á¿È¡Ñª½¬ÑùÆ·0.5mLÓÚ10mLÀëÐĹÜÖУ¬×¼È·¼ÓÈë2.5mLÒÒë棬ÎÐÐý2minºó£¬³¬Éù10min£¬ÔÚ 4500r/minתËÙÏÂÀëÐÄ5min¡£ÒÆÈ¡ÉÏÇåÒºÓõªÆø´µ¸É£¬ÓÃ1mLµÄ50%ÒÒëæË®¶¨ÈÝ £¬¹ý0.22¦ÌmÂËĤ £¬¹©LC-MS-MS·ÖÎö¡£
±í1 °¢Íз¥ËûÍ¡ÔÚESI(+)[M+H]+ µÄMRMģʽϵÄÖÊÆײÎÊý
Table 1 Test parameters for Atorvastatin in MRM
*¶¨Á¿Àë×Ó¶Ô(quantitative ion pair)
2 ½á¹ûÓëÌÖÂÛ
2.1·½·¨µÄÏßÐÔ·¶Î§¡¢ Ïà¹ØÐÔ¼°¼ì³öÏÞʵÑé
ÒÔÔÚѪ½¬¿Õ°×ÑùÆ·»ùÌåÖÐÁùµãÌí¼Ó±ê׼Ʒ·¨ÖÆ×÷УÕýÇúÏß, 7µãÌí¼Óˮƽ·Ö±ðÊÇ0.1ng/mL¡¢0.2ng/mL¡¢0.5ng/mL¡¢1ng/mL¡¢5ng /mL¡¢10ng/mL¡¢20ng/mL¡£°´±¾ÎÄ·½·¨½øÐмӱê»ØÊÕÊÔÑ飬½á¹û±íÃ÷£¬·½·¨´Ë·¶Î§ÄÚÏßÐÔÏà¹Ø£¬Ïà¹ØϵÊýr=0.9998£¬µ±ÐÅÔë±ÈS /N¡Ý10ʱ£¬¶¨Á¿ÏÂÏÞLOQΪ0.1 ng/mL¡£
2.2·½·¨µÄ¾«ÃܶȺͻØÊÕÂÊ
È¡¿Õ°×Ѫ½¬£¬·Ö±ð¾«È·¼ÓÈëÊÊÁ¿µÄ°¢Íз¥ËûÍ¡±ê×¼ÈÜÒº£¬ÅäÖƳÉŨ¶ÈΪ0.2 ng/mL¡¢2 ng/mL.10 ng/mLµÄѪ½¬ÑùÆ·¸÷6·Ý£¬°´1.4²½Öè´¦ÀíÔÚͬÈÕÄÚÖظ´²â¶¨5´Î£¬²¢Á¬Ðø5Ìì²â¶¨£¬¼ÆËãÈÕÄÚ¡¢ÈÕ¼äµÄ¾«Ãܶȡ£µÃµ½µÄÈÕÄÚ¾«ÃܶÈ(RSD%)·Ö±ðΪ2.62¡¢3.11¡¢1.97£¬Èռ侫ÃܶȷֱðΪ3.55¡¢ 5.65¡¢4.98¡£°¢Íз¥ËûÍ¡0.2 ng/mL¡¢2 ng/mL¡¢10 ng/mLÈý¸öˮƽŨ¶ÈµÄ²â¶¨»ØÊÕÂʽá¹û¼û±í2¡£
±í2 ¿Õ°×Ѫ½¬°¢Íз¥ËûÍ¡µÄÌí¼Ó»ØÊÕÂʺ;«ÃܶÈ(n=6)
Table 2 Recoveries and precisions of Atorvastatin at different fortified levels (n=6)
2.3Îȶ¨ÐÔÊÔÑé
È¡¿Õ°×Ѫ½¬.¾«È·¼ÓÈëÊÊÁ¿µÄ°¢Íз¥ËûÍ¡±ê×¼ÈÜÒº£¬·Ö±ðÅäÖƳÉŨ¶ÈΪ0.5ng/mLºÍ2 ng/mLѪ½¬ÈÜÒº£¬°´1.4ÏîÏÂѪ½¬´¦Àí·½·¨²Ù×÷£¬·Ö±ðÓÚ 0¡¢2¡¢4¡¢8¡¢10hʱ½øÐÐÉ«Æ×·ÖÎö£¬¼Ç¼·åÃæ»ý¡£½á¹û£¬RSD·Ö±ðΪ3.56%ºÍ4.14%¡£±íÃ÷ÑùƷѪ½¬ÈÜÒºÔÚ10hÄÚÎȶ¨¡£
ͼ2°¢Íз¥ËûÍ¡ÔÚMRMÌõ¼þ϶þÖÖÀë×ÓµÄÆ×ͼ
Fig.2 Two ion chromatograms of Atorvastatin in MRM
2.4ʵÑéÌõ¼þµÄÓÅ»¯ÌÖÂÛ
ÊÔÑéÖбȽÏÁ˼״¼ÒÒËá炙º³åÒº¡¢ÒÒëæÒÒËá炙º³åÒº¡¢¼×´¼Ë®ºÍÒÒëæË®[3-6]ËÄÖÖÁ÷¶¯ÏàÌåϵ£¬½á¹û±íÃ÷£¬ÒÔÒÒëæÒÒËá炙º³åÒº×÷ΪÁ÷¶¯ÏàµÃµ½µÄ·åÐÍ×îºÃ£¬³ö·åʱ¼äÒ²½ÏÎȶ¨¡£Õâ¿ÉÄÜÓÉÓÚË®ÏàÖм×ËáÌá¸ßÁË´ý²âÎïÔÚESIÕýÀë×ÓµçÅçÎíÖеÄÀë×Ó»¯Ð§ÂÊ£¬ÒÒËáï§Ôòʹ¼ì²âÎï³ö·åʱ¼ä½ÏΪÎȶ¨¡£Òò´Ë±¾ÎÄÑ¡ÔñÓÃÒÒëæ ÒÒËá炙º³åÒº×÷ΪÁ÷¶¯Ï࣬µÃµ½µÄÆ×ͼ·åÐεĶԳơ¢³ö·åʱ¼äºÍÁéÃô¶È¾ù½ÏÀíÏë(¼ûͼ2)¡£
²Î ¿¼ ÎÄ Ï×
[1]ÕÔ±ù.°¢Íз¥ËûÍ¡µÄÁÙ´²Ñо¿½øÕ¹[J]. ÖйúÒ©·¿£¬2010,21(24):203-204.
[2]Plosker GL£¬Wagstaf AJ.Fluvastatin£ºa review of its pharmaeology and use in the management og hypereholesterolaemia[J].Drugs, 1996, 51:433.
[3]½ªéª£¬ÑîÓÀ¸ï£¬ÐíÑ©Í¢£¬µÈ. LC-MS-MS·¨²â¶¨ÈËѪ½¬Öа¢Íз¥Ëû͡Ũ¶È[J]. ҩѧʵ¼ùÔÓÖ¾ 2 0 1 1, 2 9(1):15-17.
[4]ºúÏþÁᣬÀî»·µÂ.UPLC-MS/MS·¨²â¶¨½¡¿µÈËѪ½¬Öеİ¢Íз¥Ëû͡Ũ¶È¼°Ò©Îï´úл¶¯Á¦Ñ§Ñо¿[J]. ÖÐÄÏҩѧ£¬2008£¬6 (4)£º400.
[5]Tatar S, Atma ca S.Determination of amlodipine in human plasma by high performance liqued chromatography with fluorescence detection [J].J Chromatogr B Biomed Sci Appl,2001,758(2):305-310.